Disclosed herein is a method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a PARP inhibitor, particularly, (R)-2-fluoro-10a-methyl-7,8,9,10,10a,11-hexahydro-5,6,7a,11-tetraazacyclohepta[def]cyclopenta[a]fluoren-4(5H)-one, a sesqui-hydrate thereof, or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a chemotherapeutic agent. Also, disclosed a pharmaceutical combination comprising a PARP inhibitor, particularly, (R)-2-fluoro-10a-methyl-7,8,9,10,10a,11-hexahydro-5,6,7a,11-tetraazacyclohepta[def]cyclopenta[a]fluoren-4(5H)-one, a sesqui-hydrate thereof, or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor, or a chemotherapeutic agent and the use thereof.本申請公開了在受試者中預防癌症、延遲癌症進展或治療癌症的方法，包括向有此需要的受試者施用PARP抑制劑(特別是(R)-2-氟-10a-甲基-7,8,9,10,10a,11-六氫-5,6,7a,11-四氮雜環庚並[def]環戊並[a]茀-4(5H)-酮，其倍半水合物，或其醫藥上可接受之鹽)與免疫檢查點抑制劑或化療劑的組合。此外，本申請公開了包含PARP抑制劑(特別是(R)-2-氟-10a-甲基-7,8,9,10,10a,11-六氫-5,6,7a,11-四氮雜環庚並[def]環戊並[a]茀-4(5H)-酮，其倍半水合物，或其醫藥上可接受之鹽)與免疫檢查點抑制劑或化療劑的藥物組合產品及其用途。
